The Story of a Drug

In the Pipeline has an interesting story of the development and apparent decline of a new fixed-dose combination drug, BiDil.  The drug in question is particularly interesting for its indication, which is, according to Lowe, probably the first “race-based pharmaceutical”:

(Blogging may be slow in the next couple of days; I’m solo dad and my son has an ear infection, it seems.  Hooray!)